FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2048324178> ?p ?o ?g. }

• W2048324178 endingPage "581" @default.
• W2048324178 startingPage "573" @default.
• W2048324178 abstract "<h3>Objectives:</h3> We present the first study to explore safety and efficacy of the human CD20 monoclonal antibody ofatumumab in relapsing-remitting multiple sclerosis (RRMS). <h3>Methods:</h3> In this randomized, double-blind, placebo-controlled study, patients received 2 ofatumumab infusions (100 mg, 300 mg, or 700 mg) or placebo 2 weeks apart. At week 24, patients received alternate treatment. Safety and efficacy were assessed. <h3>Results:</h3> Thirty-eight patients were randomized (ofatumumab/placebo, n = 26; placebo/ofatumumab, n = 12) and analyzed; 36 completed the study. Two patients in the 300-mg group withdrew from the study because of adverse events. No unexpected safety signals emerged. Infusion-related reactions were common on the first infusion day but not observed on the second infusion day. None of the patients developed human anti-human antibodies. Ofatumumab was associated with profound selective reduction of B cells as measured by CD19⁺ expression. New brain MRI lesion activity was suppressed (>99%) in the first 24 weeks after ofatumumab administration (all doses), with statistically significant reductions (<i>p</i> < 0.001) favoring ofatumumab found in new T1 gadolinium-enhancing lesions, total enhancing T1 lesions, and new and/or enlarging T2 lesions. <h3>Conclusions:</h3> Ofatumumab (up to 700 mg) given 2 weeks apart was not associated with any unexpected safety concerns and was well tolerated in patients with RRMS. MRI data suggest a clinically meaningful effect of ofatumumab for all doses studied. Results warrant further exploration of ofatumumab in RRMS. <h3>Classification of evidence:</h3> This study provides Class II evidence that in patients with RRMS, ofatumumab compared with placebo does not increase the number of serious adverse events and decreases the number of new MRI lesions." @default.
• W2048324178 created "2016-06-24" @default.
• W2048324178 creator A5003010065 @default.
• W2048324178 creator A5012415764 @default.
• W2048324178 creator A5018686207 @default.
• W2048324178 creator A5021435946 @default.
• W2048324178 creator A5065791505 @default.
• W2048324178 creator A5078067575 @default.
• W2048324178 creator A5085187558 @default.
• W2048324178 creator A5087172990 @default.
• W2048324178 date "2014-01-22" @default.
• W2048324178 modified "2023-10-14" @default.
• W2048324178 title "Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: A phase 2 study" @default.
• W2048324178 cites W1685882185 @default.
• W2048324178 cites W1886620195 @default.
• W2048324178 cites W1965235365 @default.
• W2048324178 cites W1965452646 @default.
• W2048324178 cites W1967838438 @default.
• W2048324178 cites W1998665596 @default.
• W2048324178 cites W2001243977 @default.
• W2048324178 cites W2023331374 @default.
• W2048324178 cites W2043591841 @default.
• W2048324178 cites W2044947137 @default.
• W2048324178 cites W2049353008 @default.
• W2048324178 cites W2073019775 @default.
• W2048324178 cites W2073579062 @default.
• W2048324178 cites W2087829760 @default.
• W2048324178 cites W2095493955 @default.
• W2048324178 cites W2101712027 @default.
• W2048324178 cites W2105167551 @default.
• W2048324178 cites W2112165124 @default.
• W2048324178 cites W2121929840 @default.
• W2048324178 cites W2124575836 @default.
• W2048324178 cites W2126529136 @default.
• W2048324178 cites W2132172916 @default.
• W2048324178 cites W2133269866 @default.
• W2048324178 cites W2141111992 @default.
• W2048324178 cites W2145634991 @default.
• W2048324178 cites W2155620154 @default.
• W2048324178 cites W2165916281 @default.
• W2048324178 cites W2916040650 @default.
• W2048324178 doi "https://doi.org/10.1212/wnl.0000000000000125" @default.
• W2048324178 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24453078" @default.
• W2048324178 hasPublicationYear "2014" @default.
• W2048324178 type Work @default.
• W2048324178 sameAs 2048324178 @default.
• W2048324178 citedByCount "230" @default.
• W2048324178 countsByYear W20483241782013 @default.
• W2048324178 countsByYear W20483241782014 @default.
• W2048324178 countsByYear W20483241782015 @default.
• W2048324178 countsByYear W20483241782016 @default.
• W2048324178 countsByYear W20483241782017 @default.
• W2048324178 countsByYear W20483241782018 @default.
• W2048324178 countsByYear W20483241782019 @default.
• W2048324178 countsByYear W20483241782020 @default.
• W2048324178 countsByYear W20483241782021 @default.
• W2048324178 countsByYear W20483241782022 @default.
• W2048324178 countsByYear W20483241782023 @default.
• W2048324178 crossrefType "journal-article" @default.
• W2048324178 hasAuthorship W2048324178A5003010065 @default.
• W2048324178 hasAuthorship W2048324178A5012415764 @default.
• W2048324178 hasAuthorship W2048324178A5018686207 @default.
• W2048324178 hasAuthorship W2048324178A5021435946 @default.
• W2048324178 hasAuthorship W2048324178A5065791505 @default.
• W2048324178 hasAuthorship W2048324178A5078067575 @default.
• W2048324178 hasAuthorship W2048324178A5085187558 @default.
• W2048324178 hasAuthorship W2048324178A5087172990 @default.
• W2048324178 hasConcept C126322002 @default.
• W2048324178 hasConcept C142724271 @default.
• W2048324178 hasConcept C18031839 @default.
• W2048324178 hasConcept C197934379 @default.
• W2048324178 hasConcept C203014093 @default.
• W2048324178 hasConcept C204232928 @default.
• W2048324178 hasConcept C204787440 @default.
• W2048324178 hasConcept C27081682 @default.
• W2048324178 hasConcept C2778714382 @default.
• W2048324178 hasConcept C2780640218 @default.
• W2048324178 hasConcept C71924100 @default.
• W2048324178 hasConcept C90924648 @default.
• W2048324178 hasConceptScore W2048324178C126322002 @default.
• W2048324178 hasConceptScore W2048324178C142724271 @default.
• W2048324178 hasConceptScore W2048324178C18031839 @default.
• W2048324178 hasConceptScore W2048324178C197934379 @default.
• W2048324178 hasConceptScore W2048324178C203014093 @default.
• W2048324178 hasConceptScore W2048324178C204232928 @default.
• W2048324178 hasConceptScore W2048324178C204787440 @default.
• W2048324178 hasConceptScore W2048324178C27081682 @default.
• W2048324178 hasConceptScore W2048324178C2778714382 @default.
• W2048324178 hasConceptScore W2048324178C2780640218 @default.
• W2048324178 hasConceptScore W2048324178C71924100 @default.
• W2048324178 hasConceptScore W2048324178C90924648 @default.
• W2048324178 hasIssue "7" @default.
• W2048324178 hasLocation W20483241781 @default.
• W2048324178 hasLocation W20483241782 @default.
• W2048324178 hasOpenAccess W2048324178 @default.
• W2048324178 hasPrimaryLocation W20483241781 @default.
• W2048324178 hasRelatedWork W1719329143 @default.
• W2048324178 hasRelatedWork W1856920652 @default.

• next